HL Financial Services LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 0.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,201,948 shares of the biopharmaceutical company’s stock after selling 21,037 shares during the quarter. Pfizer makes up 2.2% of HL Financial Services LLC’s investment portfolio, making the stock its 13th largest holding. HL Financial Services LLC’s holdings in Pfizer were worth $114,310,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Northstar Group Inc. increased its position in Pfizer by 0.4% in the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 35 shares during the period. Peregrine Asset Advisers Inc. increased its position in Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC increased its position in Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 50 shares during the period. River Wealth Advisors LLC increased its position in Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after buying an additional 55 shares during the period. Finally, Meridian Wealth Management LLC increased its position in Pfizer by 0.5% in the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 57 shares during the period. Hedge funds and other institutional investors own 69.79% of the company’s stock.

Shares of Pfizer Inc. (PFE) opened at $36.93 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market capitalization of $220,130.00, a price-to-earnings ratio of 22.66, a P/E/G ratio of 2.29 and a beta of 1.01. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.61 EPS. equities analysts forecast that Pfizer Inc. will post 2.6 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.68%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 78.53%.

Pfizer declared that its board has approved a share repurchase program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

PFE has been the topic of several recent analyst reports. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Wednesday, December 27th. Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Monday. Goldman Sachs Group set a $36.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Finally, BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Friday, December 15th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and an average price target of $38.12.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last three months, insiders sold 29,450 shares of company stock worth $1,065,220. Insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/01/23/hl-financial-services-llc-has-114-31-million-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.